Novartis - Q1 FY2026 Earnings Analysis
Analysis of Novartis Q1 FY2026 earnings, focused on the drag from US generic erosion, continued strength across key growth brands, pipeline and business-development momentum, and whether launch execution in oncology, neuroscience, and cardiovascular assets can offset the near-term profit pressure.
Novartis reported Q1 net sales of $13.11 billion and core EPS of $1.99, both below market expectations of roughly $13.44 billion and $2.10, respectively. Reported results reflected the expected hit from US generic erosion, which more than offset strong momentum across the company’s core growth drivers and left net sales down 5% in constant currency.
The quarter still showed substantial underlying franchise strength. Kisqali, Pluvicto, Kesimpta, Leqvio, Scemblix, and Fabhalta all posted strong double-digit constant-currency growth, while core operating income declined 14% in constant currency to $4.9 billion as lower sales and higher R&D investment compressed margin to 37.3%.
Adjusted EPS vs. consensus breakdown — primary performance driver, segment revenue contribution, and gross margin trajectory relative to prior guidance...
Segment-by-segment revenue analysis, margin profile, and management commentary on demand trajectory vs. consensus range expectations...
Forward guidance implications for the sector, supply chain read-throughs, and investment implications for the broader competitive landscape...